Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.
IDF 2017 Prof Sattar reports on the results of the DiRECT trial evaluating a weight management program with huge implications for clinical practice. Almost half of the patients in the intervention group had remission of T2DM 1 year after the start of the trial.
Based on the results of the SUSTAIN trial, semaglutide is approved by the FDA for the treatment of T2DM patients.
The DIRECT trial evaluated a weight management program delivered by primary care. On average, weight reduced by 10 kg and almost half achieved and maintained remission of T2DM at 12 months after starting the intervention.
Prof. John Deanfield states that the introduction of two new drug classes with CV benefits can really make a difference for the CV outcomes of high-risk diabetic patients
AHA 2017 Analysis of CANVAS program compared use of canagliflozin in primary or secondary prevention and found a greater benefit on CV, renal and death outcomes in those with existing CVD.
In this educational program, which was held at the ESC Congress 2017 in Barcelona, Spain, epigenetic regulation of gene expression in patients at high CV risk with diabetes was reviewed
AHA 2017 An analysis of the EXSCEL trial examined whether risk at baseline predicted the effect of exenatide on mortality and MACE.
AHA 2017 A sub-analysis of the EMPA-REG OUTCOME examined whether the benefits of empaglifozin are preserved in diabetic patients with and without PAD.
In post-ACS type 2 diabetic patients at high CV risk, there is a significant association between baseline hsCRP values and future CV outcomes.
Differences in cognitive performance between diabetic patients and individuals with normal glucose levels can be explained by hyperglycemia and by BP-related variables, but not by insulin resistance.
In the TOPCAT study, diabetes and its microvascular complications carried important prognostic information regarding adverse outcomes in HFpEF patients.